الفهرس 
EPIDEMIOLOGY AND ETIOLOGY
Preventive measuresOnly 14 pages are availabe for public view
 |  | from | 205 |  |  |
| | | from | 205 | | |
Abstract
Prostate cancer is the second most common cancer in men
and the seventh leading cause of male cancer death
worldwide; as there are an estimated 1,600,000 new cases of
prostate cancer and 366,000 prostate cancer deaths annually
(Fitzmaurice et al., 2017).
Among the predisposing factors are: age, race, smoking,
and in a small percentage of patients, a familial genetic
component. Most of prostate cancer cases are adenocarcinomas
(Jack et al., 2014).
PCa is now recognized as one of the most important
medical problems facing the male population. Although, there
are only few studies about this entity in Egypt.
In our study, we reviewed medical records of 101
patients including demographic data and clinic-pathological
factors were reported, including age, sex, performance status
(ECOG), co-morbidities, personal habits, tumor characteristics,
surgery, radical treatment, metastatic treatment, treatment
response and survival rates were collected.
Our population under study had a median age of 69 years
(range: 42-85), majority of our patients (94%) had good ECOG
performance status (≤ 2), (44.6%) of the patients were
presented to us with metastatic disease, most common
symptoms at presentation were prostatism in 72.8% of patients
and bony aches in 18.8%.The mean Gleason score among studied population was
mean 7.37. Metastatic patients represented 45.5%, localized
represented 44.6% and locally advanced 9.9%. Median overall
survival of metastatic patients was 26 months and median OS
of non-metastatic was 38 months. Median PFS was 17 months
and the median DFS 29 months.
In our study overall survival showed statistically significant
difference with performance status, and stage group. DFS was
found to be statistically significant with performance status and
risk stratification.
Prostate cancer is a serious medical problem affecting
predominantly the elderly men. The prolonged latency, high
prevalence, and morbidity associated with significant mortality
make prostate cancer an immediate medical problem to resolve.
Diagnostic tests including PSA for early detection, and the
advances in other diagnostic and therapeutic procedures have
led to a steady decline in the disease-specific mortality with the
reduction in high-risk prostate cancers.
Prostate cancer is a very complex disease and the
decision-making process requires the clinician to balance
clinical benefits, life expectancy, comorbidities and potential
treatment related side effects. Accurate prediction of clinical
outcomes may help in the difficult process of making decisions
related to prostate cancer.